315 related articles for article (PubMed ID: 32751630)
1. Proteomics and Metabolomics for Cystic Fibrosis Research.
Liessi N; Pedemonte N; Armirotti A; Braccia C
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751630
[TBL] [Abstract][Full Text] [Related]
2. The proteome speciation of an immortalized cystic fibrosis cell line: New perspectives on the pathophysiology of the disease.
Puglia M; Landi C; Gagliardi A; Breslin L; Armini A; Brunetti J; Pini A; Bianchi L; Bini L
J Proteomics; 2018 Jan; 170():28-42. PubMed ID: 28970102
[TBL] [Abstract][Full Text] [Related]
3. Post-translational modifications of CFTR: insight into protein trafficking and cystic fibrosis disease.
Amaral MD; Farinha CM
FEBS J; 2013 Sep; 280(18):4395. PubMed ID: 23680006
[No Abstract] [Full Text] [Related]
4. A Proteomic Survey of the Cystic Fibrosis Transmembrane Conductance Regulator Surfaceome.
Iazzi M; Sadeghi S; Gupta GD
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511222
[TBL] [Abstract][Full Text] [Related]
5. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
Farinha CM; Matos P; Amaral MD
FEBS J; 2013 Sep; 280(18):4396-406. PubMed ID: 23773658
[TBL] [Abstract][Full Text] [Related]
6. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis enters the proteomics scene: new answers to old questions.
Ollero M; Brouillard F; Edelman A
Proteomics; 2006 Jul; 6(14):4084-99. PubMed ID: 16791827
[TBL] [Abstract][Full Text] [Related]
8. Serum-Based Proteomics Profiling in Adult Patients with Cystic Fibrosis.
Benabdelkamel H; Alamri H; Okla M; Masood A; Abdel Jabar M; Alanazi IO; Alfadda AA; Nizami I; Dasouki M; Abdel Rahman AM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050003
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
10. Genotype and phenotype in cystic fibrosis.
Zielenski J
Respiration; 2000; 67(2):117-33. PubMed ID: 10773783
[TBL] [Abstract][Full Text] [Related]
11. Genetics of Cystic Fibrosis: Clinical Implications.
Egan ME
Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site.
Treharne KJ; Crawford RM; Xu Z; Chen JH; Best OG; Schulte EA; Gruenert DC; Wilson SM; Sheppard DN; Kunzelmann K; Mehta A
J Biol Chem; 2007 Apr; 282(14):10804-13. PubMed ID: 17289674
[TBL] [Abstract][Full Text] [Related]
13. ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.
Pankow S; Bamberger C; Calzolari D; Martínez-Bartolomé S; Lavallée-Adam M; Balch WE; Yates JR
Nature; 2015 Dec; 528(7583):510-6. PubMed ID: 26618866
[TBL] [Abstract][Full Text] [Related]
14. Biosynthesis of cystic fibrosis transmembrane conductance regulator.
Pranke IM; Sermet-Gaudelus I
Int J Biochem Cell Biol; 2014 Jul; 52():26-38. PubMed ID: 24685677
[TBL] [Abstract][Full Text] [Related]
15. Application of mass spectrometry to study proteomics and interactomics in cystic fibrosis.
Balch WE; Yates JR
Methods Mol Biol; 2011; 742():227-47. PubMed ID: 21547736
[TBL] [Abstract][Full Text] [Related]
16. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomic profiling reveals differentially regulated proteins in cystic fibrosis cells.
Rauniyar N; Gupta V; Balch WE; Yates JR
J Proteome Res; 2014 Nov; 13(11):4668-75. PubMed ID: 24818864
[TBL] [Abstract][Full Text] [Related]
18. Introduction to section II: omics in the biology of cystic fibrosis.
Balch WE
Methods Mol Biol; 2011; 742():189-91. PubMed ID: 21547733
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation.
Arora K; Yarlagadda S; Zhang W; Moon C; Bouquet E; Srinivasan S; Li C; Stokes DC; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L364-74. PubMed ID: 27261451
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
Mickle JE; Cutting GR
Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
